Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research

Executive Summary

The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.

You may also be interested in...



UK’s NICE Not Convinced By Cannabis-Based Medicines

New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.

UK Pilot To Generate Real World Data On Medicinal Cannabis Use

Drug Science, a UK charity, is about to launch a 20,000-patient pilot project looking at the use of medicinal cannabis for conditions like chronic pain, multiple sclerosis and Tourette’s syndrome. It says a special licensing status for such products could eventually be possible.

French To Launch Two-Year Medicinal Cannabis Pilot Project

A two-year pilot program in France will look at the practicalities of prescribing medicinal cannabis for patients with one of five specific conditions.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS125583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel